Biotech Startups

Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates. Founded in 2013, it uses a cell-free protein synthesis platform to engineer vaccines for children and adults.

7 investors

Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

7 investors

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.

7 investors

Medivis develops augmented reality and AI technology for surgical navigation and clinical training, giving surgeons real-time imaging to guide procedures and reduce surgical errors. The company serves hospitals and medical centers, with its systems deployed across institutions in the United States.

7 investors

Waypoint Bio uses artificial intelligence, computer vision, and pooled screening to conduct deep phenotyping across thousands of cell therapy designs, enabling the discovery and optimization of superior cell therapy candidates for development.

7 investors

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.

7 investors

Wild Microbes uses synthetic biology to engineer microbes sourced from diverse wild biomes into production hosts for biomanufacturing high-performance ingredients. Its product pipeline spans emulsifiers, cleansers, vitamins, supplements, and industrial chemicals for partners seeking renewable, microbe-made inputs.

7 investors

Windfall Bio develops microbial-based solutions that convert methane into valuable products for industrial and agricultural customers. The company uses naturally occurring microorganisms to enable commercial-scale methane mitigation across industries.

7 investors

ZAGENO operates a lab supply procurement platform that lets pharma, biotech, and life sciences teams search, compare, and order over 50M SKUs from more than 6,000 suppliers through a single system. It adds guided buying, supplier management, real-time order tracking, AI tools, and integrations with ERP and P2P systems like Coupa, SAP, and NetSuite to serve procurement, R&D, and finance teams.

7 investors

Zya develops naturally-derived enzymes that change how the body processes food after eating, aiming to improve nutrition without altering taste. Its technology is offered to food brands as an ingredient in the food technology and nutrition space.

7 investors

J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.

7 investors

Metagen Therapeutics (メタジェンセラピューティクス) is a biotech venture developing fecal microbiota transplantation (FMT) therapies and medical services based on gut microbiome research, including an FMT drug candidate (MGT-006) for ulcerative colitis. Based in Japan, it operates across drug discovery and medical services and runs a stool donation platform to source raw material.

7 investors

4baseCare delivers personalized cancer care using genomic data, AI analytics, and clinico-genomic datasets tailored to different populations. The company serves oncology patients and healthcare systems globally, focusing on precision medicine and treatment outcomes across diverse genetic backgrounds.

6 investors

64x Bio develops cell-line engineering and production technologies to overcome manufacturing bottlenecks in advanced and next-generation therapies. It serves biopharma and therapeutics developers by combining large-scale parallelized screening with computational analysis to engineer high-yield cell lines.

6 investors

A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.

6 investors

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

6 investors

A pharmaceutical company that develops medicines and vaccines for patients globally.

6 investors

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

6 investors

Acodis provides AI-powered document automation and data extraction for quality and compliance teams, primarily in regulated industries like pharmaceuticals and life sciences. The platform automatically extracts, categorizes, and validates data from complex documents including PDFs, scans, and handwritten text, achieving 96-99%+ accuracy while maintaining audit-ready compliance.

6 investors

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

6 investors

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.

6 investors

Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system. The company partners with biopharma firms to accelerate the development of transformative protein therapeutics from discovery through clinical progression.

6 investors

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.

6 investors

Aether Biomedical develops bionic hands and rehabilitation devices for upper limb amputees using bio-signal processing technology. The company aims to make advanced prosthetics accessible and affordable globally.

6 investors